JP2021523198A5 - - Google Patents

Info

Publication number
JP2021523198A5
JP2021523198A5 JP2020564142A JP2020564142A JP2021523198A5 JP 2021523198 A5 JP2021523198 A5 JP 2021523198A5 JP 2020564142 A JP2020564142 A JP 2020564142A JP 2020564142 A JP2020564142 A JP 2020564142A JP 2021523198 A5 JP2021523198 A5 JP 2021523198A5
Authority
JP
Japan
Prior art keywords
composition according
therapeutic
aav virus
young
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020564142A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523198A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/032092 external-priority patent/WO2019222132A1/en
Publication of JP2021523198A publication Critical patent/JP2021523198A/ja
Publication of JP2021523198A5 publication Critical patent/JP2021523198A5/ja
Priority to JP2023191118A priority Critical patent/JP2024028696A/ja
Pending legal-status Critical Current

Links

JP2020564142A 2018-05-14 2019-05-14 幼若対象におけるaavベクターの安定的発現 Pending JP2021523198A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023191118A JP2024028696A (ja) 2018-05-14 2023-11-08 幼若対象におけるaavベクターの安定的発現

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862671271P 2018-05-14 2018-05-14
US62/671,271 2018-05-14
PCT/US2019/032092 WO2019222132A1 (en) 2018-05-14 2019-05-14 Stable expression of aav vectors in juvenile subjects

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023191118A Division JP2024028696A (ja) 2018-05-14 2023-11-08 幼若対象におけるaavベクターの安定的発現

Publications (2)

Publication Number Publication Date
JP2021523198A JP2021523198A (ja) 2021-09-02
JP2021523198A5 true JP2021523198A5 (cg-RX-API-DMAC7.html) 2022-05-24

Family

ID=66770562

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020564142A Pending JP2021523198A (ja) 2018-05-14 2019-05-14 幼若対象におけるaavベクターの安定的発現
JP2023191118A Pending JP2024028696A (ja) 2018-05-14 2023-11-08 幼若対象におけるaavベクターの安定的発現

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023191118A Pending JP2024028696A (ja) 2018-05-14 2023-11-08 幼若対象におけるaavベクターの安定的発現

Country Status (13)

Country Link
US (2) US20200069819A1 (cg-RX-API-DMAC7.html)
EP (1) EP3794112A1 (cg-RX-API-DMAC7.html)
JP (2) JP2021523198A (cg-RX-API-DMAC7.html)
KR (1) KR20210008491A (cg-RX-API-DMAC7.html)
CN (1) CN112424345A (cg-RX-API-DMAC7.html)
AR (1) AR117427A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019270972A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020023159A2 (cg-RX-API-DMAC7.html)
CA (1) CA3100000A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020012167A (cg-RX-API-DMAC7.html)
SG (1) SG11202010832YA (cg-RX-API-DMAC7.html)
TW (1) TW202016298A (cg-RX-API-DMAC7.html)
WO (1) WO2019222132A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6994018B2 (ja) 2016-07-26 2022-01-14 バイオマリン ファーマシューティカル インコーポレイテッド 新規アデノ随伴ウイルスキャプシドタンパク質
KR20210008501A (ko) 2018-05-09 2021-01-22 바이오마린 파머수티컬 인크. 페닐케톤뇨증을 치료하는 방법
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
TW202208632A (zh) 2020-05-27 2022-03-01 美商同源醫藥公司 用於恢復pah基因功能的腺相關病毒組成物及其使用方法
KR20230078805A (ko) 2020-11-02 2023-06-02 바이오마린 파머수티컬 인크. 아데노-연관 바이러스의 농축 공정
WO2023034980A1 (en) 2021-09-03 2023-03-09 Bomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023034990A1 (en) 2021-09-03 2023-03-09 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
US20240384242A1 (en) 2021-09-03 2024-11-21 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
JP2024534894A (ja) 2021-09-03 2024-09-26 ビオマリン プハルマセウトイカル インコーポレイテッド Aavカプシド組成物及び送達方法
WO2023034989A1 (en) 2021-09-03 2023-03-09 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
EP4396201A1 (en) 2021-09-03 2024-07-10 BioMarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
UY40443A (es) 2022-09-22 2024-02-15 Biomarin Pharm Inc Tratamiento de la miocardiopatía con vectores de genoterapia con aav
UY40442A (es) 2022-09-22 2024-02-15 Biomarin Pharm Inc Tratamiento de la miocardiopatía arritmogénica con vectores de genoterapia con aav
EP4598590A4 (en) * 2022-10-08 2026-05-27 Lingyi Biotech Co Ltd CONSTRUCTION TO IMPROVE GENE EXPRESSION
CN115896135B (zh) * 2022-11-02 2024-03-01 苏州诺洁贝生物技术有限公司 优化的pah基因和表达盒及其用途
CN116350801A (zh) * 2022-11-22 2023-06-30 四川至善唯新生物科技有限公司 一种重组腺相关病毒载体的药物组合物及其用途
WO2025214477A1 (en) 2024-04-12 2025-10-16 Skyline Therapeutics (Shanghai) Co., Ltd. Treatment of genetic cardiomyopathies with aav gene therapy vectors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531A (en) 1849-06-19 Beed musical instrument
US298A (en) 1837-07-29 Process for purifying salt-water preparatory to manufacturing salt
EP0127839B1 (en) 1983-05-27 1992-07-15 THE TEXAS A&M UNIVERSITY SYSTEM Method for producing a recombinant baculovirus expression vector
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
DK518384A (da) 1984-01-31 1985-07-01 Idaho Res Found Vektor til fremstilling af et gen-produkt i insektceller, fremgangsmaade til dens fremstilling samt dens anvendelse
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
WO1999003496A1 (en) 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
WO2003074714A1 (en) 2002-03-05 2003-09-12 Stichting Voor De Technische Wetenschappen Baculovirus expression system
US7943374B2 (en) * 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
US7943379B2 (en) 2008-04-30 2011-05-17 Nationwide Children's Hospital, Inc. Production of rAAV in vero cells using particular adenovirus helpers
ES2985035T3 (es) 2008-09-15 2024-11-04 Uniqure Biopharma B V Mutante de polipéptido de factor IX, sus usos y su procedimiento de producción
GB201210357D0 (en) 2012-06-12 2012-07-25 Ucl Business Plc Factor VIII sequences
ES2813698T3 (es) 2013-09-12 2021-03-24 Biomarin Pharm Inc Vectores de AAV que comprenden un gen que codifica el factor VIII
JP2018535929A (ja) * 2015-09-24 2018-12-06 バイオマリン ファーマシューティカル インコーポレイテッド アデノ随伴ウイルス第viii因子ベクター、関連ウイルス粒子、及びそれらを含む治療的製剤
US10143760B2 (en) * 2015-10-28 2018-12-04 Sangamo Therapeutics, Inc. Liver-specific constructs, factor VIII expression cassettes and methods of use thereof
PE20231949A1 (es) 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
WO2018170310A1 (en) * 2017-03-15 2018-09-20 The University Of North Carolina At Chapel Hill Polyploid adeno-associated virus vectors and methods of making and using the same

Similar Documents

Publication Publication Date Title
Gane et al. Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: results from randomized clinical trials
Day et al. Advances and limitations for the treatment of spinal muscular atrophy
Martinez et al. Can we cure hepatitis B virus with novel direct‐acting antivirals?
TWI620568B (zh) 用於治療b型肝炎及d型肝炎感染之方法
JP2018535929A5 (cg-RX-API-DMAC7.html)
Andrade Intranasal drug delivery in neuropsychiatry: focus on intranasal ketamine for refractory depression
CN109467566B (zh) 用于治疗和/或预防与肝炎病毒相关的疾病或病症的双二氮杂双环化合物
KR20170029577A (ko) B형 간염 및 d형 간염 바이러스 감염의 치료 방법
JPWO2018193902A1 (ja) マイクロrnaによるb型肝炎ウイルスに対する抗ウイルス効果
CN114729360A (zh) 降低病毒分子水平的方法
Marrapu et al. Hepatitis B functional cure: Current and future perspective
Ho et al. Targeting the innate immune system in treating hepatitis B: prospects for functional cure
JP2023513487A5 (cg-RX-API-DMAC7.html)
JP7850132B2 (ja) SARS-CoV-2感染患者におけるアウトカムを改善するための吸入インターフェロン-ベータ
JP2022518354A5 (cg-RX-API-DMAC7.html)
RU2020140634A (ru) Стабильная экспрессия векторов на основе аденоассоциированного вируса у несовершеннолетних пациентов
RU2023105585A (ru) Стабильная экспрессия векторов на основе аденоассоциированного вируса у несовершеннолетних пациентов
WO2021224646A1 (en) Method for the treatment of rna virus involved diseases
EP4121095A1 (en) Methods and compositions for the treatment of viral disease using granulocyte-macrophage colony-stimulating factor (gm-csf)
RU2595862C2 (ru) Способ профилактики или лечения заболеваний, связанных с пониженной плотностью интерфероновых рецепторов
CN115835877A (zh) 病毒感染引起的器官衰竭的预防和治疗
Mtewa et al. SARS-CoV-2 vaccine development
Shafer A SARS-CoV-2 antiviral therapy score card
RU2668538C1 (ru) Способ восстановления плотности интерфероновых рецепторов для профилактики или лечения заболеваний, связанных с пониженной плотностью интерфероновых рецепторов
Harford et al. TP53 Gene Therapy as a Potential Treatment for Patients with COVID-19. Viruses 2022, 14, 739